您使用的浏览器不受支持。
本网站的某些功能可能无法正常运行。为获得最佳的用户体验,请使用Chrome、Firefox、Safari或Edge浏览本网站。

新闻室

公告

Date

Announcement

   
September 16, 2021

Repligen Announces Agreement to Acquire Avitide Inc. Read More

September 9, 2021

Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
Read More

September 3, 2021

Repligen Extends Long Term Supply Agreement with Cytiva for Affinity Ligands. Read More

2021年6月22日

Repligen Corporation Announces Agreement to Acquire Polymem S.A. Read More

February 8, 2021

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

2020年10月27日

Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions. Read More

2020年10月1日

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines. Read More

2020年6月29日

Repligen Announces Agreement to Acquire Engineered Molding Technology. Read More

2019年4月4日

Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies.  Read More

Septermber 4, 2018

Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors. Read More

2018年6月28日

Repligen选择Purolite Life Sciences作为新型高性能配基商业化合作伙伴。 阅读全文

2018年6月27日

Repligen宣布与Navigo Proteins达成下一代亲和配基独家合作开发协议。 阅读全文

2017年6月23日

Repligen Corporation与 Spectrum Inc. 宣布合并。 阅读全文

2016年12月15日

Repligen acquires TangenX Technology Corporation.  Read More

2016年10月4日

Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification.  Read More

2016年4月4日

Repligen 收购 Atoll GmbH。 阅读全文

 

最新动态

Date

Title

出版物

     

July 26, 2021

Repligen Corporation set to significantly expand bioprocessing manufacturing capactiy and create 130+ new jobs in Waterford

IDA Ireland

2021年6月13日

Repligen buys Frech filtraion firm Polymem Dan Stanton
BioProcess International

2021年5月19日

Coronavirus Spike Protein Captures Resin Available for Future Deployment GEN

February 12, 2021

New Affinity Resin for COVID-19 Vaccine Purification

GEN

February 10, 2021

Repligen and Navigo target next-wave COVID vaccines with affinity resin

Dan Stanton
BioProcess International
2020年12月17日

America's Best Mid-size Companies
Repligen: #15

Andrea Murphy, Hank Tucker
Forbes
2017年11月19日 Repligen CEO Tony Hunt Knows Why Success Takes Time Marilyn Munch
Investor's Business Daily
2020年10月28日 Repligen strengthens downstream offering with $200m ARTeSYN acquisition Dan Stanton
BioProcess International
2020年10月8日

Navigo and Repligen Team on COVID-19 Vaccine Affinity Resin

Dan Stanton
BioProcess International
September 1, 2020

Continuous Processing: A Step on the Way to Bioprocess 4.0

Gareth John Macdonald
GEN
July 1, 2020

Repligen boosting single-use portfolio with Engineered Molding Technology buy

BPI Staff
BioProcess International
February 24, 2020

Repligen up on OPUS® and Gene Therapy Demand

Dan Stanton
BioProcess International
2019年10月1日 Using Alternating Tangential Flow with Fed-Batch Cultures

GEN

2019年8月12日 Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application.

Samsung BioLogics’ cell culture technique to cut production life by 30%
 

Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application 

Samsung BioLogics implants cell-culturing tech
 
Samsung Biologics

Pulse News

Yahoo News

Korea Biomed
2019年5月20日 OPUS focus: Repligen expands to support chromatography demand Dan Stanton
BioProcess International

 


新闻联系方式

Sondra Newman
高级总监,投资者关系

press @ repligen.com

电话:781.250.0111
免费电话:800.622.2259
传真:781.250.0115

下载 Repligen 商标